Y-mAbs Therapeutics (NASDAQ:YMAB) Director Ashu Tyagi purchased 430,174 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $6,882,784.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Y-mAbs Therapeutics stock traded down $0.28 during trading on Thursday, reaching $24.44. The stock had a trading volume of 30,300 shares, compared to its average volume of 927,926. Y-mAbs Therapeutics has a 52 week low of $22.50 and a 52 week high of $28.03.
Y-mAbs Therapeutics Company Profile
Featured Article: Discover Your Risk Tolerance
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.